StreetInsider.com News Articles

Form 8-K Pharma-Bio Serv, Inc. For: May 15

Fri, 15 May 2026 17:02:00 -0400

si-local-file:///var/storage/secattach/20260515/26507556.html

Form 8-K Pharma-Bio Serv, Inc. For: May 15

Fri, 15 May 2026 17:02:00 -0400

si-local-file:///var/storage/secattach/20260515/26507556.html

Form ARS Pharma-Bio Serv, Inc. For: Oct 31

Thu, 16 Apr 2026 16:20:00 -0400

si-local-file:///var/storage/secattach/20260416/26325305.html

Form ARS Pharma-Bio Serv, Inc. For: Oct 31

Thu, 16 Apr 2026 16:20:00 -0400

si-local-file:///var/storage/secattach/20260416/26325305.html

Form DEF 14A Pharma-Bio Serv, Inc. For: Apr 15

Thu, 16 Apr 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260416/26325231.html

Form DEF 14A Pharma-Bio Serv, Inc. For: Apr 15

Thu, 16 Apr 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260416/26325231.html

Form 8-K Pharma-Bio Serv, Inc. For: Mar 17

Tue, 17 Mar 2026 17:19:00 -0400

si-local-file:///var/storage/secattach/20260317/26176596.html

Form 8-K Pharma-Bio Serv, Inc. For: Mar 17

Tue, 17 Mar 2026 17:19:00 -0400

si-local-file:///var/storage/secattach/20260317/26176596.html

Pharma-Bio Serv Announces Results for the Quarter Ended January 31, 2026

Tue, 17 Mar 2026 17:05:00 -0400

DORADO, PUERTO RICO / ACCESS Newswire / March 17, 2026 / Pharma-Bio Serv, Inc. ("Pharma-Bio Serv" or the "Company") (OTCQB:PBSV), a compliance, project management and technology transfer support consulting firm that provides services to the pharmaceutical, biotechnology, chemical, medical device, cosmetic, food and allied products industries, today announced that revenues for the quarter ended January 31, 2026 were approximately $2.3 million, a decrease of approximately $0.2 million when compared to the same period last year. Net income for the quarter ended January 31, 2026 was $32,860, an improvement of $24,324 when compared

Pharma-Bio Serv Announces Results for the Quarter Ended January 31, 2026

Tue, 17 Mar 2026 17:05:00 -0400

Form 10-Q Pharma-Bio Serv, Inc. For: Jan 31

Tue, 17 Mar 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260317/26176262.html

Form 10-Q Pharma-Bio Serv, Inc. For: Jan 31

Tue, 17 Mar 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260317/26176262.html

Form 10-K/A Pharma-Bio Serv, Inc. For: Oct 31

Fri, 27 Feb 2026 16:26:00 -0400

si-local-file:///var/storage/secattach/20260227/26082213.html

Form 10-K/A Pharma-Bio Serv, Inc. For: Oct 31

Fri, 27 Feb 2026 16:26:00 -0400

si-local-file:///var/storage/secattach/20260227/26082213.html

Form 8-K Pharma-Bio Serv, Inc. For: Jan 29

Thu, 29 Jan 2026 17:07:00 -0400

si-local-file:///var/storage/secattach/20260129/25917743.html

Form 8-K Pharma-Bio Serv, Inc. For: Jan 29

Thu, 29 Jan 2026 17:07:00 -0400

si-local-file:///var/storage/secattach/20260129/25917743.html

Pharma-bio Serv, Inc. (PBSV) Declares $0.075 Special Dividend; 13.9% Yield

Thu, 29 Jan 2026 17:01:18 -0400

Pharma-bio Serv, Inc. (OTC: PBSV) declared a special dividend of $0.075 per share.

The dividend will be payable on March 20, 2026, to stockholders of record on February 27, 2026, with an ex-dividend date of February 26, 2026.

The annual yield on the dividend is 13.9 percent.

For a dividend history and other dividend-related data on Pharma-bio Serv, Inc. (PBSV) click here.

Pharma-bio Serv, Inc. (PBSV) Declares $0.075 Special Dividend; 13.9% Yield

Thu, 29 Jan 2026 17:01:18 -0400

Pharma-bio Serv, Inc. (OTC: PBSV) declared a special dividend of $0.075 per share.

The dividend will be payable on March 20, 2026, to stockholders of record on February 27, 2026, with an ex-dividend date of February 26, 2026.

The annual yield on the dividend is 13.9 percent.

For a dividend history and other dividend-related data on Pharma-bio Serv, Inc. (PBSV) click here.

Pharma-Bio Serv Announces Full Year Results and Special Dividend

Thu, 29 Jan 2026 17:00:00 -0400

DORADO, PR / ACCESS Newswire / January 29, 2026 / Pharma-Bio Serv, Inc. ("Pharma-Bio Serv" or the "Company") (OTCQB:PBSV), a regulatory affairs, quality, compliance, project management and technology transfer support consulting firm that provides services to the pharmaceutical, biotechnology, medical device, cosmetic, food and allied products industries, today announced that revenues for the year ended October 31, 2025 were approximately $9.0 million, a decrease of approximately $0.5 million when compared to last year. Additionally, a net loss for the year ended October 31, 2025 was reported of approximately $0.1 million, an improvement

Pharma-Bio Serv Announces Full Year Results and Special Dividend

Thu, 29 Jan 2026 17:00:00 -0400

Form 10-K Pharma-Bio Serv, Inc. For: Oct 31

Thu, 29 Jan 2026 16:50:00 -0400

si-local-file:///var/storage/secattach/20260129/25917479.html

Form 10-K Pharma-Bio Serv, Inc. For: Oct 31

Thu, 29 Jan 2026 16:50:00 -0400

si-local-file:///var/storage/secattach/20260129/25917479.html

Form 4 Pharma-Bio Serv, Inc. For: Jan 10 Filed by: Perlysky Dov

Wed, 14 Jan 2026 08:49:00 -0400

si-local-file:///var/storage/secattach/20260114/25847373.html

Form 4 Pharma-Bio Serv, Inc. For: Jan 10 Filed by: Perlysky Dov

Wed, 14 Jan 2026 08:49:00 -0400

si-local-file:///var/storage/secattach/20260114/25847373.html

Form 4 Pharma-Bio Serv, Inc. For: Jan 10 Filed by: MICHEL KIRK WHEELER

Wed, 14 Jan 2026 08:49:00 -0400

si-local-file:///var/storage/secattach/20260114/25847374.html